These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 37268399

  • 1. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P, Mannangatti P, Das SK, Fisher PB, Emdad L.
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [Abstract] [Full Text] [Related]

  • 2. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X, Fan W, Xu Z, Chen H, He Y, Yang G, Yang G, Hu H, Tang S, Wang P, Zhang Z, Xu P, Yu M.
    Oncotarget; 2016 Dec 06; 7(49):81110-81122. PubMed ID: 27835602
    [Abstract] [Full Text] [Related]

  • 3. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
    Liu ZD, Shi YH, Xu QC, Zhao GY, Zhu YQ, Li FX, Ma MJ, Ye JY, Huang XT, Wang XY, Xu X, Wang JQ, Zhao W, Yin XY.
    Cancer Lett; 2024 Mar 31; 585():216640. PubMed ID: 38290659
    [Abstract] [Full Text] [Related]

  • 4. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
    Panzeri V, Manni I, Capone A, Naro C, Sacconi A, Di Agostino S, de Latouliere L, Montori A, Pilozzi E, Piaggio G, Capurso G, Sette C.
    Mol Oncol; 2021 Feb 31; 15(2):579-595. PubMed ID: 33159833
    [Abstract] [Full Text] [Related]

  • 5. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER, Wright CA, James M, Cooper SJ.
    BMC Cancer; 2023 Jun 08; 23(1):524. PubMed ID: 37291514
    [Abstract] [Full Text] [Related]

  • 6. FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.
    Lu J, Yang Y, Liu X, Chen X, Song W, Liu Z.
    Cell Death Dis; 2023 Nov 01; 14(11):713. PubMed ID: 37914721
    [Abstract] [Full Text] [Related]

  • 7. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 01; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 8. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L.
    Tumour Biol; 2016 Nov 01; 37(11):15283-15291. PubMed ID: 27696296
    [Abstract] [Full Text] [Related]

  • 9. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
    Capula M, Perán M, Xu G, Donati V, Yee D, Gregori A, Assaraf YG, Giovannetti E, Deng D.
    Drug Resist Updat; 2022 Sep 01; 64():100864. PubMed ID: 36115181
    [Abstract] [Full Text] [Related]

  • 10. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
    Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R.
    Nature; 2015 Nov 26; 527(7579):525-530. PubMed ID: 26560028
    [Abstract] [Full Text] [Related]

  • 11. Glial cell-derived soluble factors increase the metastatic potential of pancreatic adenocarcinoma cells and induce epithelial-to-mesenchymal transition.
    García-Reyes B, Kuzmanov I, Schneider R, Schneiker B, Efferz P, Kalff JC, Wehner S.
    J Cancer Res Clin Oncol; 2023 Nov 26; 149(15):14315-14327. PubMed ID: 37572121
    [Abstract] [Full Text] [Related]

  • 12. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
    Luo W, Yang G, Qiu J, Luan J, Zhang Y, You L, Feng M, Zhao F, Liu Y, Cao Z, Zheng L, Zhang T, Zhao Y.
    Cancer Med; 2019 Oct 26; 8(14):6403-6413. PubMed ID: 31475468
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Mori M, Doki Y.
    Sci Rep; 2017 Feb 15; 7():42339. PubMed ID: 28198398
    [Abstract] [Full Text] [Related]

  • 14. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A, Zhou Y, Zhao T, Tang X, Zhou B, Xu J.
    Cancer Chemother Pharmacol; 2021 Aug 15; 88(2):343-357. PubMed ID: 33993382
    [Abstract] [Full Text] [Related]

  • 15. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.
    Gastroenterology; 2015 Dec 15; 149(7):1932-1943.e9. PubMed ID: 26255562
    [Abstract] [Full Text] [Related]

  • 16. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, Hill R.
    Mol Cancer Ther; 2016 May 15; 15(5):1043-52. PubMed ID: 26939701
    [Abstract] [Full Text] [Related]

  • 17. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q, Liu X, Yao X, Li R, Liu G, Jiang H, Li K, Chen Q, Huang X, Chang Q, Xu G, Zhu H, Shi P, Zhao B.
    J Exp Clin Cancer Res; 2022 Sep 15; 41(1):274. PubMed ID: 36109793
    [Abstract] [Full Text] [Related]

  • 18. Tumor Microenvironment Modulates Invadopodia Activity of Non-Selected and Acid-Selected Pancreatic Cancer Cells and Its Sensitivity to Gemcitabine and C18-Gemcitabine.
    Carvalho TMA, Audero MM, Greco MR, Ardone M, Maggi T, Mallamaci R, Rolando B, Arpicco S, Ruffinatti FA, Pla AF, Prevarskaya N, Koltai T, Reshkin SJ, Cardone RA.
    Cells; 2024 Apr 23; 13(9):. PubMed ID: 38727266
    [Abstract] [Full Text] [Related]

  • 19. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K, Toden S, Ravindranathan P, Han H, Goel A.
    Carcinogenesis; 2017 Oct 01; 38(10):1036-1046. PubMed ID: 29048549
    [Abstract] [Full Text] [Related]

  • 20. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X, Zhao P, Wang C, Xin B.
    Biochem Biophys Res Commun; 2019 Mar 19; 510(4):508-514. PubMed ID: 30737032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.